Kymera Therapeutics, Inc. (KYMR)

NASDAQ

$85.62

-$4.06 (4.53%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$84.58$90.33

Open $87.58

52 Week Range

$19.45$103.00

Previous Close $89.68

Market Cap6.16B

Volume987.45K

Avg Volume966.05K

P/E (TTM)-25.33

EPS (TTM)$-3.38

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Kymera Therapeutics, Inc.

DEC112025

Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Source: GlobeNewsWire•4 days ago

WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the c...

DEC82025

Kymera Therapeutics Announces Proposed Public Offering

Source: GlobeNewsWire•7 days ago

WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that ...

DEC82025

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

Source: GlobeNewsWire•8 days ago

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) pat...

DEC52025

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Source: GlobeNewsWire•10 days ago

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025 WATERTOWN, Mass....

NOV252025

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Source: GlobeNewsWire•21 days ago

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phase 1b AD trial with data to be reported in December...

NOV242025

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Source: GlobeNewsWire•22 days ago

WATERTOWN, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that ...

NOV32025

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Source: GlobeNewsWire•43 days ago

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that ...

OCT282025

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

Source: GlobeNewsWire•49 days ago

WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third qua...

OCT272025

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

Source: GlobeNewsWire•50 days ago

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies...